MethylGene Announces the Appointment of Peggy Mulligan
News Mar 22, 2012
MethylGene Inc. has announced the appointment of Peggy Mulligan, FCA to the Company's Board of Directors.
"Peggy is a financial and audit expert, and a well respected business leader. We look forward to her guidance as we plan for the future", said Charles Grubsztajn, President and CEO of MethylGene.
Peggy most recently served as Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals International, Inc (formerly Biovail Corporation), a multinational pharmaceutical company listed on both the New York Stock Exchange and Toronto Stock Exchange.
During her tenure, she co-led the merger and subsequent integration with Valeant Pharmaceuticals International, Inc. She is currently a member of the Board of Directors of Ontario Power Generation Inc. ("OPG") and Chair of OPG's Human Resources & Compensation Committee.
From 2005 to 2007 Peggy served as Executive Vice President, Chief Financial Officer and Treasurer of Linamar Corporation.
Previously Peggy spent eleven years in various roles at the Bank of Nova Scotia, most recently as Executive Vice President, Systems & Operations.
Before joining the Bank of Nova Scotia she was an Audit Partner with Price Waterhouse. In 2003 and 2004 Ms. Mulligan was named one of Canada's Top 100 Most Powerful Women by the Women's Executive Network.
She holds a B. Math (Honours) from the University of Waterloo and she is a Fellow of the Institute of Chartered Accountants (FCA) of Ontario.
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018